Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus

Condition(s) targeted: Hypertension

Intervention: Micardis® (Drug); MicardisPlus® (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

The primary objective is to evaluate the effect of the treatment with Micardis® or MicardisPlus® on blood pressure. Secondary objectives are the effect of Micardis® / MicardisPlus® on metabolic parameters (triglycerides, cholesterol, blood glucose and HbA1c) in patients with essential hypertension and diabetes mellitus

Official title: Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Change from Baseline in systolic blood pressure (SBP)

Change from Baseline in diastolic blood pressure (DBP)

Secondary outcome:

Assessment of efficacy by investigator on a 6-point scale

Assessment of metabolic effect on a 4-point scale

Change from Baseline in laboratory parameters

Assessment of tolerability by investigator on a 5-point scale

Number of patients with adverse events

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age > 18 years

- Hypertension

- Diabetes mellitus

Exclusion Criteria:

- Age < 18 years

Starting date: January 2006
Last updated: September 16, 2014